Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

roteins from the manufacturing medium and storage solution.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide healthcare in the areas of:

  • Behavioral Health and Gastro Intestinal conditions
  • Rare Diseases
  • Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for patients, physicians, policymakers, payors and our shareholders.

http://www.shire.com

FORWARD - LOOKING STATEMENTS - "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:

  • Shire's products may not be a commercial success;
  • revenues from ADDERALL XR are subject to generic erosion;
  • the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues and earnings;
  • Shire relies on a single source for manufacture of certain of its products and a disruption to the supply chain for those products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis;
  • Shire uses third party manufacturers to manufacture many of its products and is reliant upon thir
    '/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... changes to Martine Rothblatt , Ph.D,s compensation program. ... United Therapeutics announced the promotion of Roger Jeffs ... David Zaccardelli , Pharm.D. to Executive Vice President ... Dr. Rothblatt,s title will change from Chairman and Chief ...
(Date:12/17/2014)... Calif. , Dec. 17, 2014 ... a Phase 2 study evaluating the investigational oral ... of patients with severe, chronic itch who are ... of care, including topical steroids and antihistamines. ... change in Visual Analog Scale (VAS) itch score ...
(Date:12/15/2014)... 15, 2014 METTLER TOLEDO is ... tool, ParticleView V19 with PVM technology , ... particle vision and measurement tool continuously captures high-resolution ... ParticleView V19 then automatically prepares a report pairing ... size and concentration changes. This compelling blend of ...
(Date:12/15/2014)... SAN DIEGO , Dec. 15, 2014 /PRNewswire/ ... a three-dimensional biology company focused on delivering breakthrough ... by the industry and collaborators of its exVive3D ... was made widely available in full commercial release ... in the field, resulting in several awards for ...
Breaking Biology Technology:United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3
... Nov. 10, 2011 ChemoCentryx, Inc. today announced positive ... 44th Annual Meeting of the American Society of Nephrology. ... robust improvements of albuminuria, serum markers of renal function, ... poster presentation titled "CCR2 Inhibition in Diabetic Mice Results ...
... CRANBURY, N.J., Nov. 10, 2011 Palatin Technologies, Inc. (NYSE ... fiscal year 2012 financial results on Tuesday, November 15, 2011 ... Palatin will also conduct a conference call and live audio ... 2011, which will include discussion of the results of operations ...
... a material that absorbs on average more than 99 ... that hits it -- a development that promises to ... of engineers at NASA,s Goddard Space Flight Center in ... Optics and Photonics conference, the largest interdisciplinary technical meeting ...
Cached Biology Technology:ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 2ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 3Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011 2NASA develops super-black material that absorbs light across multiple wavelength bands 2NASA develops super-black material that absorbs light across multiple wavelength bands 3
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/11/2014)... CHICAGO , Nov. 11, 2014  Forensicon, Inc., ... eDiscovery firm, is pleased to announce the promotion of ... to Director of Digital Forensics. In Schiff,s new role ... out the team of digital forensics examiners and provide ... Photo - http://photos.prnewswire.com/prnh/20141110/157719 ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... November 18, 2009Quantitative polymerase chain reaction (qPCR) technology ... expansion as a result of advances such as ... optimization-free multiplexing, reports Genetic Engineering & Biotechnology News ... simultaneously quantify specific DNA sequences is increasing its ...
... moa, a giant extinct bird, has revealed a new geological ... in the Proceedings of the National Academy of Sciences ... University of Adelaide has reconstructed a history of marine barriers, ... of years, using the first complete genetic history of the ...
... , , KIEV, Ukraine, Nov. 17 ... including designer fashions, precious gems, antiques and fine art, has ... around the world. The International Chamber of Commerce estimates ... However, an exciting new technology can give brands and ...
Cached Biology News:Extinct moa rewrites New Zealand's history 2Innovative Document Security Technology Proves Powerful in Avoiding Counterfeit Products 2Innovative Document Security Technology Proves Powerful in Avoiding Counterfeit Products 3
... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
... Visualizer Extraction Kit is manufactured for DNA ... damage byexposure to UV light. The Purification ... often used for DNA-cloning work. The conventional ... and exposure of UV light damages DNA ...
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
Biology Products: